AccueilMédia /  Communiqués  /  09/03/2009

Oroxcell a présenté un poster VALIDATION OF THE RECONSTRUCTED HUMAN EPIDERMIS (RHE) SKIN IRRITATION ASSAY FOR FULL REPLACEMENT OF THE DRAIZE TEST

au congrès international de l’APGI, qui s’est déroulé à Versailles, en France, les 9 et 10 Mars 2009.

Auteurs : C Tornier 1, MH Roux 2, E Sache 2, JI Pachot 2, C Amsellem 3, I Goulet 3, N Alépée 4, JR Meunier 4 and A de Brugerolle 1, 1 SkinEthic Laboratories – Nice, France, 2 Oroxcell – Romainville, France, 3 EPISKIN SNC – Lyon, France, 4 L’Oréal – Aulnay, France,

Abstract : The Directive 67/548/ECC or OECD TG 404 to fully replace the in vivo Draize skin irritation test, was reinforced with the 7th Amendment of the Cosmetic Directive and the REACH regulation. Two reconstructed human epidermis models, EpiDerm and EpiSkin, were scientifically validated with the reliability, as for EpiSkin, to discriminate skin irritants (R38) from non-irritants (no label) as defined with EU risk phrases. The aim of this study was to assess weather the in vitro Reconstructed Human Epidermis (RHE) model, commercialized by SkinEthic, Laboratories could be an alternative to the historical Draize rabbit test.

Consulter le (PDF)